Ratna Bhavaraju Sanka, MD
Neuromuscular Medicine · San Antonio, TXNPI 1679786651
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $38,366 of the $56,125 with a category attached, or 68.4%. 17 manufacturers reported payments, led by Argenx US, Inc. at 41.1% of the total.
Across 90 payments — averaging $623.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$23K
- Amgen$7K
- CSL Behring$6K
- Janssen Global Services, LLC$6K
- PTC Therapeutics, Inc.$6K
- AstraZeneca$4K
- plus $4K from 11 others
Across 199 payments — averaging $5127.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$531K
- AstraZeneca$150K
- Amgen$125K
- PTC Therapeutics, Inc.$94K
- Amicus Therapeutics, Inc.$47K
- CSL Behring$29K
- plus $44K from 4 others
What the payments were for
- Consulting fees$38,36668%
- Speaking & faculty fees$9,49817%
- Travel & lodging$5,0339%
- Food & beverage$2,8665%
- Education$3621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 30 | $23,089 |
| Amgen | 8 | $7,081 |
| CSL Behring | 14 | $6,401 |
| Janssen Global Services, LLC | 6 | $5,764 |
| PTC Therapeutics, Inc. | 7 | $5,753 |
| AstraZeneca | 4 | $3,856 |
| Roche Products Limited | 1 | $1,522 |
| Sanofi | 3 | $1,432 |
| Biogen | 7 | $355 |
| UCB, Inc. | 2 | $259 |
| Alnylam Pharmaceuticals Inc. | 2 | $134 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $124 |
| Ipsen Biopharmaceuticals, Inc | 1 | $123 |
| Genentech USA, Inc. | 1 | $95 |
| Blueprint Medicines Corporation | 1 | $87 |
| Tanabe Pharma America, Inc. | 1 | $28 |
| Kedrion Biopharma, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromuscular medicine providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 62 | $920,335 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 65 | $916,937 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 28 | $644,457 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 56 | $631,210 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 15 | $457,527 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 24 | $386,724 |
| Nurtec OdtRimegepant Sulfate | 11 | $25,221 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $18,419 |
| QuliptaAtogepant | 12 | $14,670 |
| Mycophenolate Mofetil | 36 | $10,245 |
| Droxidopa | 25 | $8,579 |
| GraliseGabapentin | 14 | $7,801 |
| Pyridostigmine Bromide | 66 | $3,169 |
| Riluzole | 13 | $2,336 |
| Pregabalin | 87 | $1,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kedrion Biopharma, Inc.Gammaked | $22 | $920,33562 claims |
| CSL BehringPrivigen | $6,401 | $916,93765 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Texason file to place this against a meaningful peer group, so we don't.
Other neuromuscular medicine in San Antonio
- Matthew WicklundSan Antonio$110K
- Cassie ChanSan Antonio$2K
- John SladkySan Antonio$29
- Yessar HussainAustin$127K
- Ashley AndersonHouston$76K
- Suur BilicilerHouston$37K
- Hakam AsaadDallas$8K
- Darine KassarSugar Land$6K
- Niloofar YariDallas$5K
- Anita MadanHouston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.